- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04152226
Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With T. Pedis
Clinical Study Protocol Number DBI-201. Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With Tinea Pedis
This is an open- label, single- dose, dose escalating evaluation of the safety and tolerability of three dose levels of DBI-001 in patients with Tinea pedis.
The purpose of the current protocol is to establish the safety and tolerability of a single application of J. lividum to the feet of patients with proven T. pedis. In addition, the effect of J liv on the T. pedis will also be evaluated.
Study Overview
Detailed Description
Open- label, single- dose, dose escalating evaluation of the safety and tolerability of three dose levels of DBI-001 in patients with Tinea pedis.
Study Objectives and Purpose The purpose of the study is to evaluate the safety and tolerability of DBI-001 in patients with Tinea pedis. Secondly to evaluate presence or persistence of J. lividum of DBI-001 following a single application of DBI-001. Thirdly to see the effect on the abundance of T. rubrum. Lastly to see the effect of a single application of DBI-001 on the signs and symptoms of interdigital T. pedis.
Tolerability will be evaluated through assessment of selected local signs and symptoms (pain / burning / stinging, pruritus, erythema, edema, and scabbing / crusting). Any local skin reaction that requires use of a concomitant therapy or study discontinuation will be reported
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Santo Domingo, Dominican Republic
- Instituto Dermatologico y Cirugia de Piel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet all of the following criteria to be included in the study:
- Witnessed, signed informed consent approved by Institutional Review Board/Independent Ethics Committee.
- A signed Health Information Portability and Accountability Act (HIPAA) authorization form which permits the use and disclosure of subject's individually identifiable health information.
- Male Subjects of any race 18 years of age and older.
- Subjects with a clinical diagnosis of interdigital T. pedis T. pedis interdigital defined as lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot (the non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea pedis moccasin).
- Provisionally confirmed diagnosis at baseline by a positive potassium hydroxide (KOH) wet mount at the clinical site.
The sum of the clinical signs and symptoms scores of the target lesion is at least 4 using the Grading and signs and symptoms of T. pedis detailed in section 6.6.1, including a minimum score of at least 2 for erythema AND a minimum score of 2 for either scaling/fissures or pruritus/burning (on a scale of 0-3, where 2 indicates moderate severity).
-
Exclusion Criteria:
Subjects with the following will be excluded from this study:
- Any dermatological conditions that could interfere with clinical evaluations.
- Any underlying disease(s) or some other dermatological condition that requires the use of interfering topical or systemic therapy.
Subjects that have not undergone the specified washout period(s) for the following topical preparations or subjects who require the concurrent use of any of the following topical medications applied to the foot:
Topical astringents and abrasives (e.g. Burrow's solution) 1 week Topical antibiotics and antifungal on the infected area (e.g. Neomycin, Miconazole, Clotrimazole, Terbinafine) 2 weeks Anti-inflammatories, corticosteroids, topical immunomodulators (e.g. Pimecrolimus, Tacrolimus) 4 weeks
- Subjects that have not undergone the specified washout period(s) for the following systemic medications or subjects who require the concurrent use of any of the following systemic medications:
Corticosteroids (including intramuscular injections) (e.g. Triamcinolone acetonide) 4 weeks Antibiotics (e.g. Tetracycline, Cephalosporins, etc.) and/or Antifungal agents (e.g. Fluconazole, Itraconazole, Terbinafine, etc.) 4 weeks Systemic immunomodulators (e.g. Cyclophosphamide, Azathioprine, Biologicals-Monoclonal Antibodies.
4 weeks
Subjects with the following will be excluded from this study:
- Any dermatological conditions that could interfere with clinical evaluations.
- Any underlying disease(s) or some other dermatological condition that requires the use of interfering topical or systemic therapy.
Subjects that have not undergone the specified washout period(s) for the following topical preparations or subjects who require the concurrent use of any of the following topical medications applied to the foot:
Topical astringents and abrasives (e.g. Burrow's solution) 1 week Topical antibiotics and antifungal on the infected area (e.g. Neomycin, Miconazole, Clotrimazole, Terbinafine) 2 weeks Anti-inflammatories, corticosteroids, topical immunomodulators (e.g. Pimecrolimus, Tacrolimus) 4 weeks
Subjects that have not undergone the specified washout period(s) for the following systemic medications or subjects who require the concurrent use of any of the following systemic medications:
Corticosteroids (including intramuscular injections) (e.g. Triamcinolone acetonide) 4 weeks Antibiotics (e.g. Tetracycline, Cephalosporins, etc.) and/or Antifungal agents (e.g. Fluconazole, Itraconazole, Terbinafine, etc.) 4 weeks Systemic immunomodulators (e.g. Cyclophosphamide, Azathioprine, Biologicals-Monoclonal Antibodies. 4 weeks
- Treatment of any type of cancer within the last 6 months.
- History of any significant internal disease (which contraindicates use of live microbiome e.g. leukemia, liver failure, cardiovascular disease)
- Subjects who are known to be allergic to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure.
- AIDS or AIDS related complex by medical history.
- Known or suspected immune suppressive medications or diseases.
- Diabetes mellitus Type I or II by medical history.
- Peripheral vascular disease based on medical history.
- Any subject not able to meet the study attendance requirements.
Subjects who have participated in any other trial of an investigational drug or device within 30 days prior to enrollment or participation in a research study concurrent with this study.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cohort 1
Cohort 1 low dose of J. lividum
|
Investigational Product
Other Names:
|
Active Comparator: Cohort 2
Cohort 2 medium dose of J. lividum
|
Investigational Product
Other Names:
|
Active Comparator: Cohort 3
Cohort 3 - high dose of J. Lividum
|
Investigational Product
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local Tolerability
Time Frame: Baseline (Day 1) to Day 28
|
Tolerability will be evaluated through assessment local signs and symptoms. Scoring for Fissuring/Cracking, Erythema, Maceration, Scaling, Pruritus, Burning/Stinging: 0 = none (complete absence)
|
Baseline (Day 1) to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy 1: Presence and Persistence of J. lividum
Time Frame: 28 Days
|
Proportion of samples at each time point in which J. lividum can be detected.
|
28 Days
|
Efficacy 2: Clinical Response
Time Frame: 28 Days
|
Changes in signs and symptoms of T. pedis Scoring Measure for Fissuring/Cracking, Erythema, Maceration, Scaling, Pruritus, Burning/Stinging: Scoring Measure: 0 = none (complete absence)
|
28 Days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DBI-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinea Pedis
-
National institute of SiddhaCompletedTinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are StudiedIndia
-
Taro Pharmaceuticals USATerminated
-
DermBiont, Inc.TerminatedInterdigital Tinea PedisDominican Republic
-
AmDermaAmDerma Pharmaceuticals, LLCCompletedInterdigital Tinea PedisUnited States
-
Ahmed A. H. AbdellatifUnknownFoot Infection Tinea PedisEgypt
-
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences...CompletedOnychomycosis/Onycholysis and Tinea PedisUnited States
-
Tinea PharmaceuticalsCompletedTinea Pedis | Tinea Cruris | Tinea CorporisUnited States, Puerto Rico, El Salvador, Belize, Honduras
-
Therapeutics, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Bausch & Lomb IncorporatedBausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Bausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisDominican Republic, Honduras
Clinical Trials on J. Lividum
-
DermBiont, Inc.TerminatedAtopic DermatitisDominican Republic
-
DermBiont, Inc.TerminatedInterdigital Tinea PedisDominican Republic
-
Radboud University Medical CenterCanisius-Wilhelmina Hospital; Johnson & Johnson Medical BV, The NetherlandsCompletedArthroplasty, Replacement, KneeNetherlands
-
International AIDS Vaccine InitiativeBrigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller UniversityActive, not recruitingHIV-1-infectionUnited States, Uganda, Kenya, Rwanda, South Africa
-
Ramos Mejía HospitalCompleted
-
Davidzon, Guido, M.D.Stanford UniversitySuspended
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingHIV-1-infectionMalawi, South Africa, Botswana
-
University of Wisconsin, MadisonNational Institute on Aging (NIA)Active, not recruiting
-
Minia UniversityCompleted
-
The Cleveland ClinicCompletedRectal CancerUnited States